Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • ML-7 Hydrochloride: Selective MLCK Inhibitor for Cardiova...

    2026-01-30

    ML-7 Hydrochloride: Driving Innovation as a Selective MLCK Inhibitor for Cardiovascular Research

    Introduction: Principle and Setup for MLCK Pathway Interrogation

    ML-7 hydrochloride (1-((5-iodonaphthalen-1-yl)sulfonyl)-1,4-diazepane hydrochloride), available from APExBIO, is a highly selective myosin light chain kinase inhibitor with a Ki of 300 nM. As a potent modulator of the cardiac myosin light chain kinase (MLCK) pathway, ML-7 hydrochloride enables researchers to precisely regulate the phosphorylation of myosin light chain (MLC), a nodal event in muscle contraction, cellular motility, and barrier function. This compound’s utility is well-established in models of ischemia/reperfusion (I/R) injury, vascular endothelial dysfunction, and atherosclerosis, offering a robust platform for dissecting the MLCK-mediated phosphorylation of myosin light chain in both in vitro and in vivo settings.

    Recent studies—such as the investigation of Spiroplasma eriocheiris entry into Drosophila S2 cells—underscore the centrality of cytoskeletal dynamics and kinase modulation in cellular invasion and viability. In these and related cardiovascular disease models, ML-7 hydrochloride delivers targeted and reproducible inhibition, supporting advanced mechanistic research and therapeutic exploration.

    Step-by-Step Workflow: Optimizing Protocols with ML-7 Hydrochloride

    Preparation and Solubilization

    • Solubility: Dissolve ML-7 hydrochloride in DMSO (≥15.95 mg/mL) for stock solutions. For aqueous protocols, water solubility is ≥8.82 mg/mL with gentle warming and ultrasonic treatment. Avoid ethanol, as ML-7 is insoluble in this solvent.
    • Storage: Aliquot and store at -20°C. Prepare working solutions immediately before use for maximal potency.

    Application in Cellular Assays

    • Cell Viability/Proliferation: Treat cultured cardiomyocytes, endothelial cells, or Drosophila S2 cells with ML-7 hydrochloride at concentrations ranging from 1–10 μM, titrating for cell type and endpoint. In neonatal rat cardiomyocytes, 5 μM ML-7 robustly inhibited rhNRG-1-induced sarcomeric reorganization, as shown in published research.
    • MLCK Pathway Analysis: For pathway interrogation, pre-treat cells with ML-7 hydrochloride 30 minutes prior to experimental stimulus (e.g., hypoxia/reoxygenation or pathogen exposure). Collect lysates for Western blot analysis of phosphorylated MLC and total MLC to confirm pathway inhibition.
    • In Vivo Cardiovascular Models: In rodent I/R injury protocols, administer ML-7 (optimal dosing: 0.5–1 mg/kg, i.p.) 10 minutes before ischemia and during reperfusion. Evaluate cardiac contractility, infarct size, and downstream protein modulation (e.g., energy metabolism, oxidative stress markers).

    Tight Junction and Barrier Function Studies

    • Use ML-7 hydrochloride in endothelial monolayer models to study regulation of tight junction proteins, such as ZO-1 and occludin, via immunofluorescence or permeability assays. Concentrations of 1–10 μM reliably modulate MLCK/MLC phosphorylation and tight junction integrity.

    Advanced Applications and Comparative Advantages

    ML-7 hydrochloride’s selectivity for MLCK over other kinases (e.g., protein kinase C, PKA) makes it ideal for dissecting MLCK-dependent processes without confounding off-target effects. In the context of cardiovascular and vascular endothelial dysfunction models, this specificity translates into clearer mechanistic insights and reproducible results. For example, in I/R injury experiments, ML-7 pre-treatment led to a significant (p<0.01) improvement in ejection fraction and a 25–35% reduction in infarct size, solidifying its translational value.

    In endothelial and epithelial barrier models, ML-7 hydrochloride’s ability to modulate tight junction proteins is leveraged for atherosclerosis research and studies of vascular permeability. This is particularly relevant when compared to less selective inhibitors, which may impact a wider array of kinases and thus confound barrier function outcomes. Furthermore, as highlighted in the scenario-driven guide, ML-7 hydrochloride from APExBIO is noted for its batch-to-batch consistency and high purity (>98%), directly addressing reproducibility challenges common in MLCK-targeted research.

    Comparatively, the article "ML-7 Hydrochloride: Novel Insights into MLCK Inhibition" extends mechanistic exploration, while "Reliable Solutions for Cardiovascular and Cell Viability" complements by offering scenario-based troubleshooting. Together, these resources provide a comprehensive toolkit for both foundational and advanced users.

    Troubleshooting and Optimization Tips

    Common Pitfalls and Solutions

    • Solubility Issues: If ML-7 hydrochloride appears turbid or precipitates, ensure complete dissolution by gentle warming (≤37°C) and ultrasonic treatment. Prepare fresh solutions for each experiment to avoid degradation.
    • Cytotoxicity at High Concentration: Titrate the inhibitor in pilot assays. Concentrations above 10 μM may cause non-specific toxicity in sensitive cell lines; always include vehicle controls.
    • Off-Target Effects: Although highly selective, use appropriate negative controls (e.g., MLCK knockdown or alternative MLCK inhibitors) to confirm specificity.
    • Reproducibility: Because ML-7 hydrochloride is sensitive to storage and freeze-thaw cycles, aliquot into single-use vials. Always use product from a reputable supplier such as APExBIO to ensure consistent purity and performance.

    Protocol Enhancements

    • For pathway readouts, supplement ML-7 hydrochloride treatment with quantitative Western blot or mass spectrometry to measure changes in MLC phosphorylation.
    • When combining with live-cell imaging, minimize DMSO content (<0.1%) to reduce background effects.
    • In infection models, such as those studying cytoskeletal rearrangements during pathogen entry (see Wei et al., 2019), synchronize ML-7 addition with pathogen exposure to precisely capture MLCK-dependent events.

    Future Outlook: Expanding the Impact of MLCK Inhibition

    ML-7 hydrochloride is poised to remain a cornerstone MLCK inhibitor for cardiovascular research, atherosclerosis, and barrier function studies. Ongoing innovations, such as CRISPR-based MLCK knockout models, will further clarify the unique contributions of MLCK-mediated phosphorylation of myosin light chain. In translational settings, the compound’s role in modeling ischemia/reperfusion injury and vascular endothelial dysfunction is expected to inform the development of novel therapeutics targeting cytoskeletal and barrier regulatory pathways.

    As new disease models emerge—including advanced infection and inflammation systems—ML-7 hydrochloride’s reproducibility, high selectivity, and ease of use will continue to support cutting-edge research. For the latest protocols and reliable supply, researchers are encouraged to consult ML-7 hydrochloride from APExBIO, ensuring the integrity and success of their experimental workflows.